Zydus Cadila’s antiviral drug “Virafin” gets emergency use nod

What is the News? Drug Controller General of India(DCGI) has granted emergency use approval for pharma major Zydus Cadila’s antiviral drug ‘Virafin’ to treat moderate COVID-19 in adults.

About Virafin Drug:
  • Virafin is an antiviral drug. It is administered subcutaneously, i.e., it is injected under the skin. “Zydus Cadila”, a pharma major, manufactured. The drug was originally approved for the treatment of liver disease caused by the hepatitis B and C virus.
  • The drug has now been repurposed for treating the moderate COVID-19 disease.
  • It has been found that when the drug was given to Covid patients in the early stage, it showed significant improvement in moderate Covid cases.
  • The drug was also found to reduce hours of supplemental oxygen required by patients.
  • Moreover, patients who were treated with the drug ‘Virafin’ were tested Covid negative within 7 days.
  • Hence, after the emergency approval, the drug will now be available on the prescription of a medical specialist for use in hospital/institutional setup.

Source: The Hindu

Print Friendly and PDF